Cover Image
市場調查報告書

肽治療的全球市場 (各用途、給藥途徑、銷售方式):全球產業分析、規模、佔有率、趨勢、預測 (2014∼2020年)

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

出版商 Transparency Market Research 商品編碼 264243
出版日期 內容資訊 英文 104 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肽治療的全球市場 (各用途、給藥途徑、銷售方式):全球產業分析、規模、佔有率、趨勢、預測 (2014∼2020年) Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
出版日期: 2015年04月27日 內容資訊: 英文 104 Pages
簡介

本報告提供全球肽治療市場相關資料、各用途、給藥途徑、銷售方式、類型、API肽及各技術調查、各地區的市場趨勢和加上主要企業簡介,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 全球肽治療市場概要

  • 簡介
  • 肽治療市場新的趨勢
    • 肽製造技術趨勢
    • 肽原料藥 (API) 的供給趨勢
  • 市場動態
    • 推動因素
      • 癌症患者、糖尿病患者的人口增加,促進新品種肽市場成長
      • 肽治療的巨大研究開發 (R&D) 開發平台促進市場成長
      • 技術進步使肽製造成本的降低
    • 阻礙因素
      • 肽結構的複雜化:API廠商的大課題
      • 法規標準的欠缺
    • 機會
      • 專利懸崖伴隨的非專利肽市場成長的預測
      • 生物科技企業和大型製藥企業的合作造成新成長的預測
  • 法規方案
  • 波特的五力分析:全球肽治療市場
  • 活動影響度分析
  • 市場誘因分析
  • 市場佔有率分析

第4章 全球肽治療市場:各用途

  • 簡介
    • 全球肽治療市場收益額:各用途 (總計9年份)
  • 癌症
    • Zoladex (goserelin)
    • Velcade (bortezomib)
    • Lupron/ Enantone/ Eligard (leuprorelin)
    • 其他
  • 心血管
    • Angiomax (bivalirudin)
    • Integrilin (eptifibatide)
  • 中樞神經系統
    • Copaxone (glatiramer)
  • 代謝障礙
    • Victoza (liraglutide)
    • Byetta (exenatide)
    • 其他
  • 感染疾病
    • Incivek (Telaprevir)
    • Victrelis (Boceprevir)
  • 血液疾病
    • Firazyr (icatibant)
    • Kalbitor (ecallantide)
  • 腸胃障礙
    • Gattex (teduglutide)
    • Linzess (linaclotide)
  • 呼吸系統障礙
  • 肢端肥大症
  • 其他的用途

第5章 全球肽治療市場:各給藥途徑

  • 簡介
    • 全球肽治療市場收益額:各給藥途徑 (總計9年份)
  • 非口服給藥途徑
  • 口服給藥途徑

第6章 (透過提供現狀),全球肽治療市場:各銷售方式

  • 簡介
    • 全球肽治療市場收益額:各銷售方式 (總計9年份)
  • 品牌、肽藥物治療
  • 非專利、肽藥物治療

第7章 全球肽治療開發中產品:概要

  • 簡介
    • 全球肽治療開發中產品的概要

第8章 全球肽治療市場:各地區

  • 簡介
    • 全球肽治療市場收益額:各地區 (總計9年份)
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區 (ROW)

第9章 建議

  • 透過嚴密的研究開發 (R&D) 活動獲得新產品
  • 在新興經濟國的設施擴張
  • 透過企業收購的迅速無機成長

第10章 企業簡介

  • Amgen Inc.
    • 企業概要
    • 財務概要
    • 產品系列
    • 產業策略
    • 最近的發展趨勢
  • AstraZeneca plc
  • Bachem Holding AG
  • CordenPharma International GmbH
  • Eli Lilly and Company
  • Ipsen S.A.
  • Lonza Group Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Novo Nordisk A/S
  • PolyPeptide Group
  • Roche Holdings AG
  • Sanofi
  • 武田藥品工業
  • Teva Pharmaceutical Industries Ltd.

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, marketing status, and geography. Application segments of the global peptide therapeutics market have been further sub-segmented by major branded peptide drugs approved by regulatory authorities across the globe. Various applications considered in the report include metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others. Market size and forecast for leading drugs such as Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza, and Zoladex has been included along with in-depth market analysis. Segmentation by marketing status explains the impact of generic drugs on the overall peptide therapeutics market. Further, market segmentation of peptide drugs by route of administration provides quantitative insights into the growing demand for convenient methods for peptide drug administration. Details on peptide drug approvals, patent expiry, mergers, acquisitions, strategic agreements, disease prevalence and other major events have been included in respective market segments.

The global peptide therapeutics market report provides market estimation and forecast for more than fifteen branded peptide drugs in the market. Further, the market is also segmented by major geographical regions, which include North America, Europe, Asia Pacific and Rest of the World. A list of pipeline drugs has also been provided in the report. This list includes potential peptide drugs in phases I, II, and III of clinical development.

Emerging trends in global peptide API production, such as development of new peptide API production technologies and strategic agreements in peptide API production have been discussed. The report also profiles key peptide API suppliers. An overview of regulatory policies has also been provided in the global peptide therapeutics market report. Based on our in-depth analysis and comprehensive market study, key factors driving and restraining the market have been discussed. A detailed event impact analysis considers regulatory approvals, patent expiry of major drugs, drug recalls and other factors in the peptide therapeutics market. The research study also incorporates the competitive scenario in these regions, where market share of seven major players in 2013 has also been provided. Relevant recommendations have been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. Fifteen major players have been profiled which include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, CordenPharma International GmbH, Eli Lilly & Co., Ipsen S.A., Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, PolyPeptide Group, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. The 104 pages global peptide therapeutics market report includes 30 figures and charts, and 14 tables.

Market size and forecast in terms of USD million for each segment in the global peptide therapeutics market has been provided for the period 2012 to 2020, considering 2012 and 2013 as the base years. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020. The peptide therapeutics market has been estimated using a bottom-up approach, where market size estimates for each drug have been summed-up to arrive at the total market size. Market forecasts have been derived considering the effect of generic drug approvals, drug recalls, disease prevalence, patent term extension, box warning and various other factors. Inputs from industry experts and key opinion leaders have validated and further refined our market estimates.

The global peptide therapeutics market has been segmented as below:

Global Peptide Therapeutics Market, by Application

  • Cancer
    • Zoladex (goserelin)
    • Velcade (bortezomib)
    • Lupron/ Enantone/ Eligard (leuprorelin)
    • Others
  • Cardiovascular
    • Angiomax (bivalirudin)
    • Integrilin (eptifibatide)
  • Central Nervous System
    • Copaxone (glatiramer)
  • Metabolic Disorders
    • Victoza (liraglutide)
    • Byetta (exenatide)
    • Others
  • Infection
    • Incivek (telaprevir)
    • Victrelis (boceprevir)
  • Hematological Disorders
    • Firazyr (icatibant)
    • Kalbitor (ecallantide)
  • Gastrointestinal Disorders
    • Gattex (teduglutide)
    • Linzess (linaclotide)
  • Respiratory Disorders
  • Acromegaly
  • Other Applications

Global Peptide Therapeutics Market, by Route of Administration

  • Parenteral
  • Oral

Global Peptide Therapeutics Market, by Marketing Status

  • Branded
  • Generic

Global Peptide Therapeutics Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
  • 1.4 List of Abbreviations
  • 1.5 Assumptions and Stipulations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
  • 2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview

  • 3.1 Introduction
  • 3.2 Emerging Trends in Peptide Therapeutics Market
    • 3.2.1 Trends in Peptide Manufacturing Technology
    • 3.2.2 Trends in Peptide API Supply
  • 3.3 Market Dynamics
    • 3.3.1 Drivers
      • 3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides
      • 3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
      • 3.3.1.3 Technological advancements have reduced total production cost of peptides
    • 3.3.2 Restraints
      • 3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
      • 3.3.2.2 Lack of regulatory standards
    • 3.3.3 Opportunities
      • 3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period
      • 3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth
  • 3.4 Regulatory Scenario
  • 3.5 Porter's Five Forces Analysis: Global Peptide Therapeutics Market
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyer
    • 3.5.3 Threat of Substitutes
    • 3.5.4 Threat of New Entrants
    • 3.5.5 Competitive Rivalry
  • 3.6 Event Impact Analysis
    • 3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
  • 3.7 Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
  • 3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications

  • 4.1 Introduction
    • 4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 - 2020 (USD Million)
  • 4.2 Cancer
    • 4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.2 Zoladex (goserelin)
    • 4.2.3 Velcade (bortezomib)
    • 4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
    • 4.2.5 Others
  • 4.3 Cardiovascular
    • 4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.2 Angiomax (bivalirudin)
    • 4.3.3 Integrilin (eptifibatide)
  • 4.4 Central Nervous System
    • 4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.4.2 Copaxone (glatiramer)
  • 4.5 Metabolic Disorders
    • 4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.5.2 Victoza (liraglutide)
    • 4.5.3 Byetta (exenatide)
    • 4.5.4 Others
  • 4.6 Infection
    • 4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.6.2 Incivek (telaprevir)
    • 4.6.3 Victrelis (boceprevir)
  • 4.7 Hematological Disorders
    • 4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.7.2 Firazyr (icatibant)
    • 4.7.3 Kalbitor (ecallantide)
  • 4.8 Gastrointestinal Disorders
    • 4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
    • 4.8.2 Gattex (teduglutide)
    • 4.8.3 Linzess (linaclotide)
  • 4.9 Respiratory Disorders
    • 4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 4.10 Acromegaly
    • 4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 4.11 Other Applications
    • 4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration

  • 5.1 Introduction
    • 5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
  • 5.2 Parenteral Route of Administration
    • 5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
  • 5.3 Oral Route of Administration
    • 5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status

  • 6.1 Introduction
    • 6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
  • 6.2 Branded Peptide Therapeutics
    • 6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.3 Generic Peptide Therapeutics
    • 6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview

  • 7.1 Introduction
    • 7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography

  • 8.1 Introduction
    • 8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 8.2 North America
    • 8.2.1 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 8.5 Rest of the World
    • 8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 9 Recommendations

  • 9.1 Rigorous research and development (R&D) would yield new products
  • 9.2 Facility expansion in emerging economies
  • 9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles

  • 10.1 Amgen, Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Financial Overview
    • 10.1.3 Product Portfolio
    • 10.1.4 Business Strategies
    • 10.1.5 Recent Developments
  • 10.2 AstraZeneca plc
    • 10.2.1 Company Overview
    • 10.2.2 Financial Overview
    • 10.2.3 Product Portfolio
    • 10.2.4 Business Strategies
    • 10.2.5 Recent Developments
  • 10.3 Bachem Holding AG
    • 10.3.1 Company Overview
    • 10.3.2 Financial Overview
    • 10.3.3 Product Portfolio
    • 10.3.4 Business Strategies
    • 10.3.5 Recent Developments
  • 10.4 CordenPharma International GmbH
    • 10.4.1 Company Overview
    • 10.4.2 Financial Overview
    • 10.4.3 Product Portfolio
    • 10.4.4 Business Strategies
    • 10.4.5 Recent Developments
  • 10.5 Eli Lilly and Company
    • 10.5.1 Company Overview
    • 10.5.2 Financial Overview
    • 10.5.3 Product Portfolio
    • 10.5.4 Business Strategies
    • 10.5.5 Recent Developments
  • 10.6 Ipsen S.A.
    • 10.6.1 Company Overview
    • 10.6.2 Financial Overview
    • 10.6.3 Product Portfolio
    • 10.6.4 Business Strategies
    • 10.6.5 Recent Developments
  • 10.7 Lonza Group Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Financial Overview
    • 10.7.3 Product Portfolio
    • 10.7.4 Business Strategies
    • 10.7.5 Recent Developments
  • 10.8 Merck & Co., Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Financial Overview
    • 10.8.3 Product Portfolio
    • 10.8.4 Business Strategies
    • 10.8.5 Recent Developments
  • 10.9 Novartis AG
    • 10.9.1 Company Overview
    • 10.9.2 Financial Overview
    • 10.9.3 Product Portfolio
    • 10.9.4 Business Strategies
    • 10.9.5 Recent Developments
  • 10.10 Novo Nordisk A/S
    • 10.10.1 Company Overview
    • 10.10.2 Financial Overview
    • 10.10.3 Product Portfolio
    • 10.10.4 Business Strategies
    • 10.10.5 Recent Developments
  • 10.11 PolyPeptide Group
    • 10.11.1 Company Overview
    • 10.11.2 Financial Overview
    • 10.11.3 Product Portfolio
    • 10.11.4 Business Strategies
    • 10.11.5 Recent Developments
  • 10.12 Roche Holdings AG
    • 10.12.1 Company Overview
    • 10.12.2 Financial Overview
    • 10.12.3 Product Portfolio
    • 10.12.4 Business Strategies
    • 10.12.5 Recent Developments
  • 10.13 Sanofi
    • 10.13.1 Company Overview
    • 10.13.2 Financial Overview
    • 10.13.3 Product Portfolio
    • 10.13.4 Business Strategies
    • 10.13.5 Recent Developments
  • 10.14 Takeda Pharmaceutical Company Limited
    • 10.14.1 Company Overview
    • 10.14.2 Financial Overview
    • 10.14.3 Product Portfolio
    • 10.14.4 Business Strategies
    • 10.14.5 Recent Developments
  • 10.15 Teva Pharmaceutical Industries Ltd.
    • 10.15.1 Company Overview
    • 10.15.2 Financial Overview
    • 10.15.3 Product Portfolio
    • 10.15.4 Business Strategies
    • 10.15.5 Recent Developments

List of Figures

  • FIG. 1 Peptide Therapeutics Market Segmentation
  • FIG. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
  • FIG. 3 Porter's Five Forces Analysis: Global Peptide Therapeutics Market
  • FIG. 4
  • FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
  • FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %)
  • FIG. 7 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 10 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
  • FIG. 11 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)
  • FIG. 12 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 15 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 16 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 17 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 18 Amgen, Inc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 19 AstraZeneca plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 20 Bachem Holding AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 21 Eli Lilly and Company: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 22 Ipsen S.A.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 23 Lonza Group Ltd.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 24 Merck & Co., Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 25 Novartis AG Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 26 Novo Nordisk A/S Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 27 Roche Holdings AG: Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 28 Sanofi: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
  • TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market
  • TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 - 2020 (USD Million)
  • TABLE 4 Global Cancer Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 7 Global Infection Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 8 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 10 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
  • TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
  • TABLE 13 Global Peptide Therapeutics Market Pipeline Overview
  • TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top